عنوان سخنرانی: ارزیابی شناختی یکپارچه به جای تشخیصهای زمانبر اختلال شناختی خفیف و بیماری آلزایمر
سخنران: دکتر سید مهدی خلیقرضوی (پژوهشگاه رویان)
چکیده سخنرانی: تشخیص زودهنگام اختلال شناختی خفیف و آلزایمر برای کنترل زوال عقلی کلیدی است. نشانگرهای زیستی دیجیتال میتوانند به شناسایی افراد و دیدن تغییرات شناختی در افراد پر خطر برای ابتلا به زوال عقلی کمک کند. علاوه بر این چنین تستهایی منجر به تحلیل پیشرفتهتر و نتایج شخصیسازی شده دقیقتر میگردد. در این سخنرانی به کاربرد هوش مصنوعی و توسعه یک تست ارزیابی شناختی در تشخیص زودهنگام این بیماریها پرداخته میشود.
ویدیوی این سخنرانی در زیر در دسترس است.
Online Seminar – Cognitive Neuroscience, fMRI
Title: Integrated Cognitive Assessment for Timely Diagnosis of Mild Cognitive Impairment and Alzheimer’s Disease
Speaker: Dr. Seyed Mahdi Khaligh Razavi
Affiliation: Royan Institute
London, UK Cofounder & Chief Science Officer, Cognetivity Itd,
Previously at:
MRC Cognition and Brain Sciences Unit, Cambridge University
CSALL, Massachusetts Institute of Technology (MIT)
Harvard catalyst
Description:
Early detection and monitoring of mild cognitive impairment (MCI) and Alzheimer’s Disease (AD) patients are key to tackling dementia and providing benefits to patients, caregivers, healthcare providers and society. Digital biomarkers can help identify and monitor subtle cognitive changes in individuals at risk of developing dementia. Furthermore, such tests are able to benefit from advanced analytics for more accurate and personalised results. Artificial intelligence (AI) and machine learning are being increasingly used for applications in Dementia research. We developed the Integrated Cognitive Assessment (ICA) which is a 5-min, self-administered, computerised cognitive assessment tool based on a rapid categorisation task. The ICA is innately independent of language and culture, and can generalise across populations without the need for collection of population-specific normative data. ICA has received CE approval for use in Europe and is cleared by FDA for use in the US. After more than 28 years of symptom therapy in AD, new disease modifying therapies are becoming available which are only effective in early stages of the disease. This further emphasizes the importance of early diagnosis, and highlights the benefits of emerging technologies such as ICA a practical solution to the significant and urgent problem of timely dementia diagnosis.
* I will give a brief summary of Cognetivity’s journey so far and walk you through some of the key findings from our research publications and clinical investigations.
Date: Monday, November 8, 2021
10:00-11:30(Tehran)
Aban 17, 1400